Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Highlights from iwCLL 2019: MRD and novel therapies

Lydia Scarfò and William Wierda • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Cyclophosphamide Fludarabine Ibrutinib Rituximab Venetoclax

William Wierda, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, and Lydia Scarfo, MD, from Vita-Salute San Raffaele University, Milan, Italy, discuss the utility of MRD as an intermediate endpoint in chronic lymphocytic leukemia (CLL) treatment. The speakers touch on immuno-chemotherapy and novel therapies introduced at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Lydia Scarfò

From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment 2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application 3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists 2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers 1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025

More from William Wierda

A deep dive into BTK degraders for the treatment of CLL 9:39
A deep dive into BTK degraders for the treatment of CLL
William Wierda • 6 Feb 2025
Barriers to the implementation of MRD-guided treatment into CLL clinical practice 2:20
Barriers to the implementation of MRD-guided treatment into CLL clinical practice
William Wierda • 27 Sep 2024
The 2024 update to the NCCN guidelines for CLL/SLL: coming soon 1:37
The 2024 update to the NCCN guidelines for CLL/SLL: coming soon
William Wierda • 27 Sep 2024
The impact of liso-cel approval on the CLL treatment landscape and barriers to its use 1:44
The impact of liso-cel approval on the CLL treatment landscape and barriers to its use
William Wierda • 27 Sep 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals